Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Siamak Daneshmand et al.|The Lancet Oncology|2021Cited by 411
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, Karla V. Ballman et al.|New England Journal of Medicine|2024Cited by 145
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 VaccineRebecca M. Shulman, Eric M. Horwitz, David S. Weinberg et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 23